Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
05 2022
Historique:
received: 27 04 2021
revised: 22 07 2021
pubmed: 11 9 2021
medline: 4 5 2022
entrez: 10 9 2021
Statut: ppublish

Résumé

The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. The PET radioligand

Identifiants

pubmed: 34503957
pii: jnumed.121.262506
doi: 10.2967/jnumed.121.262506
pmc: PMC9051593
doi:

Substances chimiques

Gallium Radioisotopes 0
Glucagon-Like Peptide-1 Receptor 0
Peptides 0

Banques de données

ClinicalTrials.gov
['NCT03350191']

Types de publication

Clinical Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

794-800

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22
pubmed: 24622317
Diabetes Obes Metab. 2019 Jan;21(1):120-128
pubmed: 30091218
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
J Clin Endocrinol Metab. 2014 May;99(5):1519-24
pubmed: 24512490
J Nucl Med. 2021 Jun 1;62(6):833-838
pubmed: 33097629
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
Diabetes. 2018 Oct;67(10):2012-2018
pubmed: 30045920
Lancet. 2018 Nov 17;392(10160):2180-2193
pubmed: 30293770
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
Lancet. 2017 Oct 7;390(10103):1664-1675
pubmed: 28781108
EJNMMI Res. 2019 Feb 15;9(1):17
pubmed: 30771019
Diabetes. 2021 Apr;70(4):842-853
pubmed: 33547046
Nucl Med Biol. 2014 Jul;41(6):471-6
pubmed: 24857864
Sci Rep. 2020 Oct 7;10(1):16758
pubmed: 33028880
J Nucl Med. 2013 Aug;54(8):1458-63
pubmed: 23761918
Diabetes Obes Metab. 2017 May;19(5):705-712
pubmed: 28094469
PLoS One. 2013 Jun 24;8(6):e67454
pubmed: 23826303
Brain Res. 2018 Nov 1;1698:213-219
pubmed: 30144405
Diabetes Obes Metab. 2008 Nov;10 Suppl 4:32-42
pubmed: 18834431
J Clin Invest. 2013 Mar;123(3):990-5
pubmed: 23454762
Nat Rev Endocrinol. 2018 Jul;14(7):390-403
pubmed: 29728598
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
J Nucl Med. 2020 Jan;61(1):112-116
pubmed: 31519801
J Diabetes Res. 2015;2015:162718
pubmed: 25688374
Am J Nucl Med Mol Imaging. 2017 Jul 15;7(3):111-125
pubmed: 28721305
J Biol Chem. 1992 Apr 15;267(11):7402-5
pubmed: 1313797
Acta Diabetol. 2017 Nov;54(11):1039-1045
pubmed: 28891030
J Biol Chem. 1993 Sep 15;268(26):19650-5
pubmed: 8396143

Auteurs

Olof Eriksson (O)

Antaros Medical AB, Uppsala, Sweden; olof.eriksson@antarosmedical.com michael.wagner@sanofi.com.
Science for Life Laboratory, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.

Irina Velikyan (I)

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Akademiska Sjukhuset, Uppsala, Sweden.

Torsten Haack (T)

R&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany.

Martin Bossart (M)

R&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany.

Iina Laitinen (I)

Global Imaging, Sanofi, Frankfurt, Germany.

Philip J Larsen (PJ)

Diabetes Research, Sanofi, Frankfurt, Germany.

Jan Erik Berglund (JE)

Clinical Trial Consultants AB, Uppsala, Sweden; and.

Gunnar Antoni (G)

Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Akademiska Sjukhuset, Uppsala, Sweden.

Lars Johansson (L)

Antaros Medical AB, Uppsala, Sweden.

Stefan Pierrou (S)

Antaros Medical AB, Uppsala, Sweden.

Joachim Tillner (J)

Translational Medicine, Sanofi, Frankfurt, Germany.

Michael Wagner (M)

R&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany; olof.eriksson@antarosmedical.com michael.wagner@sanofi.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH